LOGIN  |  REGISTER
Astria Therapeutics
Terns Pharmaceuticals

ChromaDex to Participate in the LD Micro Invitational XIII

May 30, 2023 | Last Trade: US$3.80 0.02 0.53

LOS ANGELES / May 30, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings.

ChromaDex’s Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, are scheduled to present on June 6th at 1:30pm Pacific Time (4:30pm Eastern Time).

ChromaDex management will also attend virtual one-on-one meetings with institutional investors throughout the day. For those interested in having a meeting with ChromaDex, please visit www.ldmicro.com for more information.

We invite interested parties to watch ChromaDex’s live presentation via this webcast link: ChromaDex Investor Presentation – LD Micro Invitational

To view ChromaDex’s profile, please use this link: http://www.ldmicro.com/profile/CDXC

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Astria Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB